GCP
NVO

GSA Capital Partners’s Novo Nordisk NVO Stock Holding History

GSA Capital Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,293
Closed -$923K – 2022
2025
Q1 		$923K Buy
+13,293
New +$1.1M 0.08% 391
2020
Q3 		– Sell
-7,376
Closed -$241K – 1343
2020
Q2 		$241K Buy
+7,376
New +$235K 0.13% 255
2018
Q4 		– Sell
-9,836
Closed -$232K – 1622
2018
Q3 		$232K Buy
+9,836
New +$240K 0.01% 1435
2015
Q4 		– Sell
-9,472
Closed -$257K – 1917
2015
Q3 		$257K Buy
+9,472
New +$268K 0.01% 1453

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

GSA Capital Partners's NVO Position: Q2 2025 in Review

GSA Capital Partners sold out of Novo Nordisk (NVO) in Q2 2025, closing a stake of 13,293 shares — an estimated $923K sold.

GSA Capital Partners first reported a position in NVO in Q3 2015 and held it in 4 quarters. The position peaked at $923K in Q1 2025. 1,481 funds tracked by Wall St. Rank hold NVO as of Q2 2025.

  • GSA Capital Partners reported no remaining Novo Nordisk position as of Q2 2025 after selling out during the quarter.
  • GSA Capital Partners sold 13,293 Novo Nordisk shares in Q2 2025, an estimated $923K.
  • GSA Capital Partners first reported a position in Novo Nordisk in Q3 2015 and held it in 4 quarters.
  • GSA Capital Partners's Novo Nordisk position peaked at $923K in Q1 2025.
  • 1,481 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2025.

Based on GSA Capital Partners's 13F filing for Q2 2025, filed 22 Jul 2025.